Market access consulting that sets a price payers will reimburse.

Market access consulting is advice on getting a medicine covered and reimbursed at a price that holds, so patients in each target market can receive it. Market access in healthcare connects a therapy to its payers, and a market access consultant compares payer criteria, access pathways and price corridors across markets to show what coverage requires. Nextyn bases that advice on interviews with payers, hospital decision-makers and clinicians in the United States, the United Kingdom and Europe.

A Nextyn market access consulting project delivers three outputs: an access benchmark for each market in scope, a comparison of price corridors across markets, and the evidence each payer expects. Each output comes from primary interviews with payers and clinicians, not from published list prices alone:

• Access benchmark: the payer criteria and access pathways in each market, side by side
• Price corridors: the range payers consider acceptable, market by market
• Evidence requirements: the clinical and economic evidence each payer type expects to see

Nextyn interviews the four groups that decide whether a therapy is reimbursed and used: national and regional payers, HTA decision-makers, hospital formulary committees and treating clinicians. The sample is matched to each market's access system, so a US health-plan review and a European HTA review each hear from the right people:

• National and regional payers and health-plan decision-makers
• HTA decision-makers who assess clinical and economic value
• Hospital pharmacy and formulary committee members
• Treating clinicians, on how price and access shape prescribing

Nextyn runs market access research in the United States, the United Kingdom, Germany, France, Italy and Spain, among other markets. Markets are agreed at scoping and follow the launch sequence, so the benchmark shows how a price set in one market affects the next. Recent Nextyn work includes health-plan and hospital research that tested price corridors and coverage assumptions for a cardiovascular launch in the United Kingdom, and an oncology access benchmark in Brazil.

Nextyn recommends market access research before the target price and the launch order are fixed, while both decisions can still change. A price agreed in one market shapes what is achievable in the next, so payer evidence gathered early informs every later launch. There are three other triggers for a benchmark: a new indication, an HTA reassessment, and a competitor launch that resets payer expectations.

A Nextyn market access project runs in four steps, from brief to read-out, and nothing is commissioned until the client approves the plan. The client sees the sample, method and price before any fieldwork, and reads every interview with the Nextyn team at the end.

1. Submit the brief: the therapy, the target markets, the launch sequence and the pricing decision to settle.
2. Receive a plan within 48 hours: which payers and clinicians Nextyn will interview, how, and what the work costs.
3. Approve the plan: fieldwork starts only after sign-off.
4. Review the read-out: every interview read together, showing where payers agree, where they conflict and what is still open.

Nextyn sends a research plan within 48 hours of receiving the brief, stating who will be interviewed, how, and what the work costs. The plan sets the fieldwork length for the markets and payer types in scope, so a two-market payer review and a seven-market benchmark each get their own timeline. Nothing is commissioned until the client approves that plan and its price.

Nextyn's market access consulting tests one therapy's price and evidence with the payers who will decide its coverage, while desk research reads list prices and past HTA decisions for other products. Desk research shows where prices have landed, and payer interviews show the criteria behind them, which decide whether a new price holds.